Dan Zhao

TL;DR: Investigations of JX06 mechanism suggested that covalent modification at C240 induced conformational changes at Arginine 286 through Van der Waals forces, thereby hindering access of ATP to its binding pocket and in turn impairing PDK1 enzymatic activity, reflecting a metabolic shift that promoted cellular oxidative stress and apoptosis.

TL;DR: Data demonstrate that 3a may be an excellent lead compound for the treatment of cancer as a first-generation subtype-selective and covalent PDK1 inhibitor.

TL;DR: A broad overview of the assays used to characterize new inhibitors of c-MET can be found in this article, where a series of representative small-molecule inhibitors from the published patent literature from 2011 to 2013 are recorded.

TL;DR: In this article, a combined computational strategy consisting of molecular modeling, molecular dynamic (MD) simulation, and quantum mechanics/molecular mechanics (QM/MM) simulation was applied to elucidate these important issues.

TL;DR: PI-273 is the first substrate-competitive, subtype-specific inhibitor of PI4KIIα, the use of which will facilitate evaluations of PI-IIα as a cancer therapeutic target, and significantly inhibited MCF-7 cell-induced breast tumor growth without toxicity.